Orchestra Biomed Holdings beats earnings by $0.01, misses revenue estimates

Orchestra Biomed Holdings Inc. reported adjusted earnings per share that exceeded Wall Street estimates by $0.01 for the latest quarter, while revenue lagged behind analyst projections.

The medical device company posted adjusted EPS of $0.21, surpassing the $0.20 consensus estimate from Refinitiv IBES data. Revenue totaled $12.3 million, missing the $13.1 million forecast.

Orchestra Biomed develops and commercializes cardiovascular devices, including its flagship product, VeraSeal, a surgical sealant used in cardiac procedures. The company has emphasized its focus on expanding commercialization efforts and pipeline development in recent quarters.

Chief Executive Officer David Hochman stated that the company remains on track with its strategic initiatives despite the revenue shortfall. "We continue to execute on our commercial and R&D plans," Hochman said in a statement. "While revenue was below expectations, we are confident in the long-term growth trajectory of our portfolio."

Analysts noted that revenue volatility has been a recurring theme for Orchestra Biomed, reflecting challenges in scaling commercial operations for its niche cardiovascular products. The company has previously highlighted delays in hospital adoption and reimbursement hurdles as key factors affecting near-term revenue performance.

Shares of Orchestra Biomed were down 5% in after-hours trading following the report, extending losses from the prior session. The stock has declined approximately 18% year-to-date, underperforming broader biotech indices.

Orchestra Biomed did not provide forward guidance in its earnings release, citing ongoing market and operational uncertainties. Investors will be closely monitoring commercial execution and pipeline milestones in the coming quarters.